O'Brien James Michael 4
4 · ENZO BIOCHEM INC · Filed Oct 30, 2017
Insider Transaction Report
Form 4
O'Brien James Michael
SVP of Finance
Transactions
- Sale
Common Stock
2017-10-27$10.28/sh−6,699$68,866→ 44,354 total - Sale
Common Stock
2017-10-27$10.28/sh−8,667$89,097→ 28,187 total - Exercise/Conversion
Stock Option (to acquire common stock)
2017-10-27$2.75/sh−6,699$18,422→ 68,501 totalExercise: $2.75From: 2015-02-04Exp: 2019-02-03→ Common Stock (6,699 underlying) - Exercise/Conversion
Common Stock
2017-10-27$2.75/sh+6,699$18,422→ 34,886 total - Exercise/Conversion
Common Stock
2017-10-27$3.40/sh+7,500$25,500→ 42,386 total - Exercise/Conversion
Common Stock
2017-10-27$4.35/sh+8,667$37,701→ 51,053 total - Sale
Common Stock
2017-10-27$10.28/sh−7,500$77,100→ 36,854 total - Exercise/Conversion
Stock Option (to acquire common stock)
2017-10-27$3.40/sh−7,500$25,500→ 61,001 totalExercise: $3.40From: 2016-01-22Exp: 2020-01-21→ Common Stock (7,500 underlying) - Exercise/Conversion
Stock Option (to acquire common stock)
2017-10-27$4.35/sh−8,667$37,701→ 52,334 totalExercise: $4.35From: 2017-03-15Exp: 2021-03-15→ Common Stock (8,667 underlying)
Footnotes (1)
- [F1]The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.